eligibility_summary
Adults ≥18 with advanced/recurrent/metastatic pancreatic adenocarcinoma after ≥1 prior systemic therapy, ECOG 0–1, measurable disease, tissue for biomarkers, adequate counts/renal/hepatic function, neg pregnancy test/contraception. Exclude: concurrent trials/therapy, active infection, neuropathy ≥G2, active CNS mets, immunosuppression/steroids, prior enfortumab or MMAE-ADC, active HBV/HCV/HIV/TB, recent CV event or RT/surgery, live vaccine, uncontrolled diabetes, comorbidity or allergy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Phase II, single-arm study in previously treated locally advanced/recurrent/metastatic pancreatic adenocarcinoma. Intervention: Enfortumab vedotin (Padcev) 1.25 mg/kg IV on days 1, 8, 15 of 28-day cycles. Drug type/mechanism: Antibody–drug conjugate (ADC). A human IgG1 monoclonal antibody targets Nectin-4 and delivers the cytotoxic payload monomethyl auristatin E (MMAE). After Nectin-4 binding and internalization, MMAE is released to inhibit tubulin polymerization, causing G2/M cell-cycle arrest and apoptosis, potential local bystander effect. Targets: Nectin-4 (PVRL4)-expressing pancreatic tumor cells, downstream impact on microtubule dynamics/mitotic spindle and cell-cycle pathways.